Tirzepatide targets two metabolic hormone pathways, which may provide enhanced appetite regulation and metabolic support for some individuals.
Key Reasons for the Ban: Lack of scientific and therapeutic rationale for combination use No added clinical benefit over individual drug therapy Increased risk of adverse drug reactions and drug interactions Potential contribution to antimicrobial resistance (in antibiotic combinations) Overall unnecessary burden on patients and healthcare systems Regulatory Action: The ban reflects Indias strengthened approach toward evidence-based medicine and rational drug use, ensuring that only safe, effective, and clinically justified drug combinations remain in the market
Antioxidant alternatives in the treatment of amyotrophic lateral sclerosis: a comprehensive review
Meta-regression was carried out to explore the possible sources of heterogeneity, such as the baseline degree of obesity involved above ( Statistical analyses were performed using Stata version 160 (Stata Corp, College Station, TX, USA) and R software (version 413)
They negatively influence neighbor cells by secreting SASP (Borodkina et al., 2018)
